QNRX
Quoin Pharmaceuticals, Ltd.11.72
+1.57+15.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
9.83MP/E (TTM)
-Basic EPS (TTM)
-29.17Dividend Yield
0%Recent Filings
8-K
Quoin seeks SFDA breakthrough status
Quoin filed for Breakthrough Medicine Designation with Saudi Arabia's SFDA for QRX003, its late-stage topical for Netherton Syndrome, on January 20, 2026. If granted, accelerated review could enable sales there by 2H 2026 via Genpharm partnership. Enrollment wraps H1 2026. Trials carry approval risks.
8-K
Approves stock option forms
Quoin Pharmaceuticals' Compensation Committee approved forms of incentive and non-qualified stock option award agreements on November 14, 2025, under its 2025 Equity Incentive Plan for directors and executives. These enable flexible vesting and exercise methods like cashless mechanisms. Termination rules vary: vested options exercisable up to 1 year post-death/disability, 3 months otherwise. No grants issued yet.
8-K
Rapamycin loadings achieved
Quoin Pharmaceuticals hit target rapamycin loadings of 4% w/w in its proprietary topical lotion and 5% w/w in a dermal patch on November 11, 2025. The company will manufacture clinical trial batches this quarter, targeting microcystic lymphatic malformations and venous malformations—indications lacking FDA-approved treatments—in 1H 2026. Progress bolsters its rare disease pipeline. Clinical timelines carry delay risks.
10-Q
Q3 FY2025 results
Quoin Pharmaceuticals posted a Q3 net loss of $3.9M, up 68% y/y from $2.3M, driven by R&D expenses doubling to $2.3M on external clinical costs for QRX003, while G&A rose 20% to $1.7M amid severance. YTD net loss widened to $11.5M from $6.7M, with operating cash burn at $8.5M; capex not disclosed so FCF not disclosed in the 10-Q. Cash fell to $1.8M and investments to $3.6M, offset by $7.6M due officers and October's $16.6M private placement plus $3.3M warrant exercises. Losses match operating losses. Cash runway extended.
8-K
Q3 loss widens; $105M funding secured
Quoin Pharmaceuticals reported Q3 2025 net loss of $3.9M, up from $2.3M last year due to higher R&D spend, yet closed a $105.3M private placement in October with $16.6M upfront to fund QRX003 Netherton trials starting Q4. Cash stood at $5.4M on Sept 30, bolstering runway into 2027. New CFO Sally Lawlor joins amid clinical momentum.
BLRX
BioLineRx Ltd.
3.01-0.17
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
CNTA
Centessa Pharmaceuticals plc
25.72-0.43
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
QNCX
Quince Therapeutics, Inc.
3.70-0.07
QTTB
Q32 Bio Inc.
2.88-0.17
QURE
uniQure N.V.
21.89+1.46
RPRX
Royalty Pharma plc
38.38-0.15
XRTX
XORTX Therapeutics Inc.
0.59-0.01